Abstract
Androgen activity plays a key role in prostate cancer progression. Androgen receptor (AR) is the main mediator of androgen activity in the prostate, through its ability to act as a transcription mediator. Here we performed a genome-wide analysis of human AR binding to promoters in the presence of an agonist or antagonist in an androgen dependent prostate cancer cell line. Many of the AR bound promoters are bound in all examined conditions while others are bound only in the presence of an agonist or antagonist. Several motifs are enriched in AR bound promoters, including the AR Response Element (ARE) half-site and recognition elements for the transcription factors OCT1 and SOX9. This suggests that these 3 factors could define a module of co-operating transcription factors in the prostate. Interestingly, AR bound promoters are preferentially located in AT rich genomic regions. Analysis of mRNA expression identified chicken ovalbumin upstream promoter-transcription factor 1 (COUP-TF1) as a direct AR target gene that is downregulated upon binding by the agonist liganded AR. COUP-TF1 immunostaining revealed nucleolar localization of COUP-TF1 in epithelium of human androgen dependent prostate cancer, but not in adjacent benign prostate epithelium. Stromal cells both in human and mouse prostate show nuclear COUP-TF1 staining. We further show that there is an inverse correlation between COUP-TF1 expression in prostate stromal cells and the rising levels of androgen with advancing puberty. This study extends the pool of recognized putative AR targets and identifies a negatively regulated target of AR – COUP-TF1 – which could possibly play a role in human prostate cancer.
Highlights
Prostate cancer is the most common non-skin cancer in males in the US, with an estimated number of 217,730 new cases in the US in 2010 [1]
We first tested the effect of androgen, or Androgen receptor (AR) antagonist on growth of LAPC4 cells in vitro compared with cells treated with vehicle alone
This phenomenon prompted scientists to explore how AR antagonist can act as agonists in hormone refractory prostate cancer
Summary
Prostate cancer is the most common non-skin cancer in males in the US, with an estimated number of 217,730 new cases in the US in 2010 [1]. Ligand bound steroid receptors were canonically believed to bind a consensus sequence in DNA that is made up of two hexameric half-sites of the consensus sequence 59-TGTTCT39, arranged as inverted repeats, separated by three nucleotides [8,9,10,11,12,13,14,15]; yet this dogma was recently contended with regard to the AR. It was recently suggested, as supported by our data, that the half site is sufficient for AR binding to DNA in the presence of androgen [16,17,18]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.